SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition, Cumulative Effect (Details) - USD ($)		Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2015	Mar. 31, 2012
Balance Sheets [Abstract]
Contract assets		$ 10,000,000
Accounts receivable		16,518,687	$ 4,655,105
Deferred revenue		0	6,400,000
Deferred royalty buy-down		(185,000)	(2,500,000)		$ (1,500,000)
Deferred tax assets, net		313,768	1,739,706
Income tax payable		704,934	68,733
Retained earnings adjustment		72,176,719	41,939,115
Endo [Member]
Balance Sheets [Abstract]
Accounts receivable		16,518,687	4,655,105
Deferred revenue			(6,400,000)	$ 8,250,000
Deferred royalty buy-down			(2,500,000)
Accounts payable and accrued expenses -third party royalties			(400,000)
Deferred tax assets, net			1,739,706
Income tax payable			0
Retained earnings adjustment			(2,900,000)
ASU 2014-09 [Member] | Endo [Member]
Balance Sheets [Abstract]
Accounts receivable			12,300,000
Deferred revenue			(100,000)
Deferred royalty buy-down			(2,900,000)
Accounts payable and accrued expenses -third party royalties			(1,000,000)
Deferred tax assets, net			400,000
Income tax payable			(1,400,000)
Retained earnings adjustment			7,300,000
Adjustments / Effect of Change Higher / (Lower) [Member] | ASU 2014-09 [Member]
Balance Sheets [Abstract]
Accounts receivable		9,700,000
Deferred tax assets, net		(1,100,000)
Income tax payable		1,900,000
Retained earnings adjustment		$ 11,200,000
Adjustments / Effect of Change Higher / (Lower) [Member] | ASU 2014-09 [Member] | Endo [Member]
Balance Sheets [Abstract]
Accounts receivable	[1]		7,600,000
Deferred revenue	[2]		6,300,000
Deferred royalty buy-down	[3]		(400,000)
Accounts payable and accrued expenses -third party royalties	[3]		(600,000)
Deferred tax assets, net	[4]		(1,300,000)
Income tax payable	[5]		(1,400,000)
Retained earnings adjustment			$ 10,200,000

[1] This adjustment represents the elimination of the one quarter lag by recognizing royalty revenues based on of XIAFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.

[2] Represents the remaining deferred revenue balance of the prepaid mark-up on cost of goods sold based on sales by non-affiliated sublicensees of Endo outside of the U.S.

[3] Represents the amortization of the royalty buy-down and third party royalties expense associated royalty revenues based on XIAFLEX net sales reported to us by Endo for the fourth quarter of 2017.

[4] To reverse a deferred tax asset associated with the deferred revenue balance of the prepaid mark-up on cost of goods sold by non-affiliated sublicensees of Endo outside of the U.S.

[5] To create a tax liability associated the elimination of the one quarter lag by recognizing royalty revenues based on of XIAFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.